A wearable infusion device comprises a reservoir that holds a liquid medicament, an outlet port that delivers the liquid medicament to a patient, a pump that displaces a volume of the liquid medicament to the outlet port when actuated, and a control that actuates the pump. A lock-out disables the device when a predefined amount of medicament has been delivered to the outlet.
|
1. A wearable infusion device comprising: a reservoir that holds a liquid medicament; an outlet port that delivers the liquid medicament to a patient; a pump that displaces a volume of the liquid medicament to the outlet port when actuated; a mechanical control that mechanically actuates the pump; and a lock-out that acts directly on the mechanical control to preclude operation of the mechanical control when a predefined amount of medicament has been delivered to the outlet.
13. A wearable infusion device comprising: a reservoir that holds a liquid medicament; an outlet port that delivers the liquid medicament to a patient; a pump that displaces a volume of the liquid medicament to the outlet port when actuated; a mechanical control that mechanically engages with the pump to actuate it; and a lock-out that acts directly on the mechanical control to disable the mechanical control and preclude actuation of the device when the medicament level in the reservoir is at a given level.
14. A wearable infusion device comprising: a reservoir that holds a liquid medicament; an outlet port that delivers the liquid medicament to a patient; a pump that displaces a volume of the liquid medicament to the outlet port when actuated; a control that mechanically engages with the pump to actuate it; a fill port communicating with the reservoir to permit the reservoir to be filled with the liquid medicament; and a lock-out that blocks the fill port to disable the device when the medicament level in the reservoir is at a given level.
15. A wearable infusion device comprising: a reservoir that holds a liquid medicament; an outlet port that delivers the liquid medicament to a patient; a pump that displaces a volume of the liquid medicament to the outlet port when actuated; a control that mechanically engages with the pump to actuate it; a fill port communicating with the reservoir to permit the reservoir to be filled with the liquid medicament; and a lock-out that blocks the fill port and disables the control to disable the device when the medicament level in the reservoir is at a given level.
5. A wearable infusion device comprising: a reservoir that holds a liquid medicament; an outlet port that delivers the liquid medicament to a patient; a pump that displaces a volume of the liquid medicament to the outlet port when actuated; a control that mechanically engages with the pump to actuate it; a lock-out that disables the device when a predefined amount of medicament has been delivered to the outlet; and a fill port communicating with the reservoir to permit the reservoir to be filled with the liquid medicament, wherein the lock-out blocks the fill port to disable the device when a predefined amount of medicament has been delivered to the outlet.
3. The device of
7. The device of
9. The device of
11. The device of
|
The present invention relates to infusion devices and more particularly to such devices that enable liquid medicaments to be conveniently and safely self-administered by a patient.
Tight control over the delivery of insulin in both type I diabetes (usually juvenile onset) and type II diabetes (usually late adult onset), has been shown to improve the quality of life as well as the general health of these patients. Insulin delivery has been dominated by subcutaneous injections of both long acting insulin to cover the basal needs of the patient and by short acting insulin to compensate for meals and snacks. Recently, the development of electronic, external insulin infusion pumps has allowed the continuous infusion of fast acting insulin for the maintenance of the basal needs as well as the compensatory doses (boluses) for meals and snacks. These infusion systems have shown to improve control of blood glucose levels. However, they suffer the drawbacks of size, cost, and complexity. For example, these pumps are electronically controlled and must be programmed to supply the desired amounts of basal and bolus insulin. This prevents many patients from accepting this technology over the standard subcutaneous injections.
Hence, there is a need in the art for a convenient form of insulin treatment which does not require significant programming or technical skills to implement to service both basal and bolus needs. Preferably, such a treatment would be carried out by an infusion device that is simple to use and mechanically driven negating the need for batteries and the like. It would also be preferable if the infusion device could be directly attached to the body and not require any electronics to program the delivery rates. The insulin is preferably delivered through a small, thin-walled tubing (cannula) through the skin into the subcutaneous tissue similar to technologies in the prior art.
While the idea of such a simple insulin delivery device is compelling, many obstacles must be overcome before such a device may become a practical realty. One problem resides in insulin supply. Patients vary greatly on the amount of insulin such a device must carry to provide treatment over a fixed time period of, for example, three days. This is one environment where one size does not fit all. Still further, such devices must be wearable with safety and not subject to possible accidental dosing. Still further, such devices must be capable of delivering an accurately controlled volume of medicament with reliability. While it is preferred that these devices include all of the forgoing features, it would be further preferred if the cost of manufacturing such a device would be economical enough so as to render the device disposable after use. As will be seen subsequently, the devices and methods described herein address these and other issues.
In one embodiment, the invention provides a wearable infusion device comprising a reservoir that holds a liquid medicament, an outlet port that delivers the liquid medicament to a patient, and a pump that displaces a volume of the liquid medicament to the outlet port when actuated. The device further includes a control that actuates the pump and a lock-out that disables the device when a predefined amount of medicament has been delivered to the outlet.
The lock-out may disable the control to disable the device when a predefined amount of medicament has been delivered to the outlet. The lock-out may be a last dose lock-out. The lock-out may disable the control when the reservoir is at a given level such as, for example, empty.
The device may further comprise a fill port communicating with the reservoir that permits the reservoir to be filled with the liquid medicament and the lock-out may block the fill port to disable the device when a predefined amount of medicament has been delivered to the outlet. In this embodiment, the lock-out may a last dose lock-out. The lock-out may be responsive to the reservoir being at a given level such as, for example, empty, to block the fill port.
In another embodiment, the lock-out may disable the control and block the fill port to disable the device when a predefined amount of medicament has been delivered to the outlet. Here also, the lock-out may be a last dose lock-out responsive to the reservoir being at a given level, such as, for example, empty, to disable the control and block the fill port.
In another embodiment, the invention provides a wearable infusion device comprising a reservoir that holds a liquid medicament, an outlet port that delivers the liquid medicament to a patient and a pump that displaces a volume of the liquid medicament to the outlet port when actuated. The device further includes a control that actuates the pump, and a lock-out that disables the control to disable the device when the medicament level in the reservoir is at a given level.
In a further embodiment, the invention provides a wearable infusion device comprising a reservoir that holds a liquid medicament, an outlet port that delivers the liquid medicament to a patient, and a pump that displaces a volume of the liquid medicament to the outlet port when actuated. The device further includes a control that actuates the pump, a fill port communicating with the reservoir to permit the reservoir to be filled with the liquid medicament, and a lock-out that blocks the fill port to disable the device when the medicament level in the reservoir is at a given level.
In a still further embodiment, the invention provides a wearable infusion device comprising a reservoir that holds a liquid medicament, an outlet port that delivers the liquid medicament to a patient, and a pump that displaces a volume of the liquid medicament to the outlet port when actuated. The device further includes a control that actuates the pump, a fill port communicating with the reservoir to permit the reservoir to be filled with the liquid medicament, and a lock-out that blocks the fill port and disables the control to disable the device when the medicament level in the reservoir is at a given level.
The features of the present invention which are believed to be novel are set forth with particularity in the appended claims. The invention, together with further features and advantages thereof, may best be understood by making reference to the following description taken in conjunction with the accompanying drawings, in the several figures of which like reference numerals identify identical elements, and wherein:
Referring now to
The enclosure 12, as will be seen subsequently, is formed by virtue of multiple device layers being brought together. Each layer defines various components of the device such as, for example, a reservoir, fluid conduits, pump chambers, and valve chambers, for example. This form of device construction, in accordance with aspects of the present invention, enables manufacturing economy to an extent rendering the device disposable after use.
The base 14 preferably includes an adhesive coating to permit the device to be adhered to a patient's skin. The adhesive coating may originally be covered with a releasable cover that may be pealed off of the base 14 when the patient endeavors to deploy the device 10. Such arrangements are well known in the art.
The device 10 may be mated with a previously deployed cannula assembly. However, it is contemplated herein that the various aspects of the present invention may be realized within a device that may be alternatively first adhered to the patient's skin followed by the deployment of a cannula thereafter.
The actuator buttons 16 and 18 are placed on opposites sides of the device 10 and directly across from each other. This renders more convenient the concurrent depression of the buttons when the patient wishes to receive a dose of the liquid medicament contained within the device 10. This arrangement also imposes substantially equal and opposite forces on the device during dosage delivery to prevent the device from being displaced and possibly stripped from the patient. As will be further seen hereinafter, the concurrent depression of the buttons is used to particular advantage. More specifically, the actuator button 16 may serve as a valve control which, when in a first position as shown, establishes a first fluid path between the device reservoir and the device pump to support pump filling, and then, when in a second or depressed position, establishes a second fluid path between the device pump and the device outlet or cannula to permit dosage delivery to the patient. As will be further seen, a linkage between the control actuator buttons 16 and 18 permits actuation of the device pump with the actuator control button 18 only when the second fluid path has been established by the first actuator control button 16. Hence, the first actuator control button 16 may be considered a safety control.
Referring now to
It may also be noted that the actuator buttons 16 and 18 are spring loaded by springs 36 and 38. The springs are provided for returning the actuator buttons to the first position after a dosage is administered.
The pump 24 of the device 10 comprises a piston pump. The pump 24 includes a pump piston 26 and a pump chamber 28. In accordance with this embodiment, the actuator control button 18 is directly coupled to and is an extension of the pump piston 26.
With further reference to
Still further, the second valve 34 is a safety valve that closes tighter responsive to increased fluid pressure within fluid conduit 46. This assures that the liquid medicament is not accidentally administered to the patient notwithstanding the inadvertent application of pressure to the reservoir, for example. In applications such as this, it is not uncommon for the reservoir to be formed of flexible material. While this has its advantages, it does present the risk that the reservoir may be accidentally squeezed as it is worn. Because the second valve only closes tighter under such conditions, it is assured that increased accidental reservoir pressure will not cause the fluid medicament to flow to the cannula.
In operation, the reservoir is first filled through the fill port 20 to a desired level of medicament. In this state, the valves 32 and 34 will be as shown. The first valve 32 will be open and the second valve 34 will be closed. This permits the piston chamber 28 to be filled after the reservoir is filled. The cannula 30 may then be deployed followed by the deployment of the device 10. In this state, the valves 32 and 34 will still be as shown. The first valve 32 will be open and the second valve 34 will be closed. This permits the pump chamber 28 to be filled through a first fluid path including conduits 42 and 44 as the piston 24 returns to its first position after each applied dose.
When the patient wishes to receive a dose of medicament, the actuator buttons are concurrently pressed. In accordance with aspects of the present invention, the linkage 52 causes the first valve 32 to close and the second valve 34 to thereafter open. Meanwhile, the second linkage 54 precludes actuation of the pump 24 until the first valve 32 is closed and the second valve 34 is opened by the first actuator button 16. At this point a second fluid path is established from the pump 24 to the cannula 30 through fluid conduits 46 and 48 and the outlet 50. The medicament is then administered to the patient through cannula 30.
Once the medication dosage is administered, the piston 24, and thus the actuator button 18, is returned under the spring pressure of spring 38 to its initial position. During the travel of the piston back to its first position, a given volume of the liquid medicament for the next dosage delivery is drawn from the reservoir into the pump chamber 28 to ready the device for its next dosage delivery.
Referring now to
The first actuator control button carries a valve timing cam 80 that rocks the rocker 72. The button 16 further carries a cam cylinder 82 and a cam pin 84 that is received into the cam cylinder 82. The spring 36 returns the actuator button 16 to its first position after each dosage delivery. The top body layer 64 forms the top portion of the device enclosure. It receives a planar cap 86 that completes fluid paths 85 partially formed in the top layer 64. Lastly, a needle 88 is provided that provides fluid coupling from the cannula (not shown) to the outlet of the device 10.
The rocker 74 opens and closes the valves 32 and 34. It is under control of the timing cam 80 carried by the first actuator control button 16. As the control button 16 is moved laterally, the cam 80 causes the rocker 74 to pivot and to apply pressure to one or the other of the valve seats 92 or 94. The shape of the cam surfaces on the rocker 74 and the cam 80 assure that the valve 34 will not open until the valve 32 closes. The cam 80 and rocker 74 thus form the first linkage 52 shown in
While the cam 80 and rocker 74 are operating the valves 32 and 34 under timing control provided by the first linkage 52, the second linkage 54 is controlling when the pump may displace liquid medicament form the pump chamber 28 to the device outlet and cannula.
As may be seen in
When the actuator buttons are in their first position as shown in
The snap action of the actuator buttons 16 and 18 provides positive assurance to the patient that a dosage of medicament was delivered. Also, because the snap action only occurs when the pump actuator button 18 completes it full travel, the patient will also know that a full dosage was delivered.
After the outer cam cylinder 82 has completed its travel over the lock cylinder 100, the ears 104 will be displaced sufficiently into space 106 to permit the cam cylinder 76 to clear the end of the lock cylinder 100 and slide over the lock tube 78. The condition of the second linkage 54 at this time is shown in
Referring now to
The enclosure 212 is formed by virtue of multiple device layers being brought together. Each layer defines various components of the device such as, for example, a reservoir, fluid conduits, pumps, and valve chambers, for example. This form of device construction, in accordance with aspects of the present invention, enables manufacturing economy to an extent rendering the device disposable after use.
The base 214 preferably includes an adhesive coating to permit the device to be adhered to a patient's skin. The adhesive coating may originally be covered with a releasable cover that may be pealed off of the base 214 when the patient endeavors to deploy the device 210. Such arrangements are well known in the art.
As will also be seen subsequently, the device 210 may be mated with a previously deployed cannula assembly. However, it is contemplated herein that the various aspects of the present invention may be realized within a device that may be alternatively first adhered to the patient's skin followed by the deployment of a cannula thereafter.
As in the previous embodiment, the actuator buttons 216 and 218 are placed on opposites sides of the device 210 and directly across from each other. This again renders more convenient the concurrent depression of the buttons when the patient wishes to receive a dose of the liquid medicament contained within the device 210. This arrangement also imposes substantially equal and opposite forces on the device during dosage delivery to prevent the device from being displaced and possibly stripped from the patient. As will be further seen hereinafter, the concurrent depression of the buttons is used to particular advantage. More specifically, the actuator button 216 may serve as a valve control which, when in a first position as shown, establishes a first fluid path between the device reservoir and the device pump to support pump filling, and then, when in a second or depressed position, establishes a second fluid path between the device pump and the device outlet or cannula to permit dosage delivery to the patient. As will be further seen, a linkage between the control actuator buttons 216 and 218 permits actuation of the device pump with the actuator control button 218 only when the second fluid path has been established by the first actuator control button 216. Hence, the first actuator control button 216 may be considered a safety control.
With continued reference to
The tactile indicator 260 being carried on the pump actuator control button 218 provides a very significant feature and advantage. As will be seen subsequently, the pump actuator button 218 has an integral extension that forms the piston 226 of the piston pump 224 as represented in
Referring now to
It may also be noted that the actuator buttons 216 and 218 are spring loaded by springs 236 and 238. The springs are provided for returning the actuator buttons to the first position after a dosage is administered.
The pump 224 of the device 210 comprises a piston pump. The pump 224 includes a pump piston 226 and a pump chamber 228. In accordance with this embodiment, the actuator control button 218 is directly coupled to and is an extension of the pump piston 226.
With further reference to
Still further, the second valve 234 is a safety valve that assures that the liquid medicament is not accidentally administered to the patient notwithstanding the inadvertent application of pressure to the reservoir, for example. In applications such as this, it is not uncommon for the reservoir to be formed of flexible material. While this has its advantages, it does present the risk that the reservoir may be accidentally squeezed as it is worn. Because of the second valve 234, it is assured that accidental reservoir pressure will not cause the fluid medicament to flow to the cannula.
In operation, the pump chamber 228 is first filled as the actuator button 218 returns to the first position after having just delivered a medicament dosage. In this state, the shuttle valve 231 is set so that the first valve 232 will be open (the reservoir 222 communicates with the fluid conduit 240) and the second valve 234 will be closed (the conduit 246 is closed off from fluid conduit 240). This establishes a first fluid path from the reservoir 222 to the pump 224 through conduits 242, 240 and 244 that permits the piston chamber 228 to be filled by the reservoir as the actuator button is returned to its first position under the influence of the spring 238.
When the patient wishes to receive another dose of medicament, the actuator buttons are concurrently pressed. In accordance with aspects of the present invention, the linkage 252 causes the first valve 232 to close and the second valve 234 to thereafter open. Meanwhile, the second linkage 254 precludes actuation of the pump 224 until the first valve 332 is closed and the second valve 334 is opened by the first actuator button 216. At this point a second fluid path is established from the pump 224 to the cannula 30 through fluid conduits 244, 240 and 246 and the outlet 250. The medicament is then administered to the patient through cannula 30.
Once the medication dosage is administered, the piston 224, and thus the actuator button 218, is returned under the spring pressure of spring 238 to its initial position. During the travel of the piston back to its first position, a given volume of the liquid medicament for the next dosage delivery is drawn from the reservoir into the pump chamber 228 as described above to ready the device for its next dosage delivery.
Referring now to
As may also be seen in
The valve chamber 290 is arranged to receive the valve shuttle bar 241 carried by and extending from the first actuator button 216. O-rings 233, 235, 237, and 239 are arranged to be seated on the shuttle bar 241 to form the first and second valves 232 and 234 respectively (
The pump actuator button 218 carries the pump piston 226 and a second portion 294 of the second linkage 254. The pump piston 226 is arranged to be received within the pump chamber 228 and the second portion 294 of the second linkage 254 is arranged to be received within the bore 295 for interacting with the first portion 292. O-rings 300 and 302 are arranged to be seated on the piston 226 to provide a seal against leakage and to prevent external contaminants from entering the piston chamber. The base layer 280 further includes fluid channels 304 that serve to form the fluid conduits illustrated in
The intermediate layer 282 is formed of flexible membrane material. A portion 296 of the intermediate layer is received over the reservoir portion 286 to form the reservoir 222 (
The top layer 284 is arranged to be received over the intermediate layer 282 and adhered to the base layer. It includes a panel 320 having a view window 318 through which the medicament level indicator line may be observed.
Lastly with respect to
Referring now to
As previously mentioned, a panel 320 of the top layer 284 has a window opening 318 to render the medicament level indicia viewable. The cover panel 320 forms a guide channel 356 that receives and confines the web second end to guide the web for linear movement in the second plane substantially transverse to the first plane. As the reservoir is filled or emptied, a glance through the window 318 will provide an indication of the level of the medicament in the reservoir 222.
Referring now to
Referring now to
Hence, from the above, it may be seen that the pump button 218 could not at first move freely while the first actuator button 216 which operates the valves could. As a result, the pump actuation lags behind the valve actuation causing the first valve 232 (
When the extension 400 of the pump button clears the abutment 388, it becomes locked in a snap action. As in the previous embodiment, this provides positive feedback to the patient that a dosage of medicament was delivered as desired. It also causes a full dose to be delivered. By virtue of the snap action of the pump actuator, only full doses may be administered.
When the medicament has been delivered, the spring loading of the actuator buttons returns the buttons to their first or initial position. During this time, the same timing provided by the block 382 is used for recharging the pump. More specifically, ramp 366 unlatches the end 401 of extension 400 by lifting rod member 404 so that 246 is closed and conduit 242 is opened before the pump is returned by the spring to its initial position. This assures that the pump does not pull medicament from the patient but only from the reservoir. As the piston 226 of the piston pump 224 returns, a full dose of the medicament is drawn up into the piston chamber 228 to ready the device for the next dosage delivery.
When the pump chamber is filled with medicament as the actuator button is returned from the second position shown in
As may be noted, the pin is L-shaped at end 323 with an L-extension 428. A capture ramp 430, integral with the actuator button, passes adjacent to the pin 322 and over the L-extension 328. This occurs when the actuator button is depressed as long as the reservoir has sufficient medicament to provide at least one more dosage delivery.
Reference may now be had to
Referring now to
While particular embodiments of the present invention have been shown and described, modifications may be made. For example, instead of manual actuation and spring loaded return of the valves used herein, constructions are possible which perform in a reversed manner by being spring actuated and manually returned. It is therefore intended in the appended claims to cover all such changes and modifications which fall within the true spirit and scope of the invention as defined by those claims.
Adams, John M., Carter, Brett J., Cross, Brett
Patent | Priority | Assignee | Title |
10258736, | May 17 2012 | Tandem Diabetes Care, Inc. | Systems including vial adapter for fluid transfer |
10279106, | May 08 2014 | TANDEM DIABETES CARE, INC | Insulin patch pump |
10549044, | Jun 09 2016 | Becton, Dickinson and Company | Spacer assembly for drug delivery system |
10603445, | Jun 09 2016 | Becton, Dickinson and Company | Needle actuator assembly for drug delivery system |
10751476, | Jun 09 2016 | Becton, Dickinson and Company | Actuator assembly for drug delivery system |
10792432, | Jun 09 2016 | Becton, Dickinson and Company | Drive assembly and spacer for drug delivery system |
11007317, | May 02 2018 | CEQUR SA | Devices and methods for providing a bolus dose in a microfluidic circuit of a pump |
11033677, | May 08 2014 | Tandem Diabetes Care, Inc. | Insulin patch pump |
11229737, | Sep 10 2014 | Becton, Dickinson and Company | Activation system and method for on-body medical devices |
11278665, | Nov 22 2016 | LTS DEVICE TECHNOLOGIES LTD | Method for delivering a therapeutic substance |
11357909, | Oct 05 2018 | LTS DEVICE TECHNOLOGIES LTD | Triggering sequence |
11357918, | Oct 16 2017 | Becton, Dickinson and Company | Spacer assembly for drug delivery device |
11654248, | Jun 09 2016 | Becton, Dickinson and Company | Needle actuator assembly for drug delivery system |
11701464, | Oct 05 2018 | LTS DEVICE TECHNOLOGIES LTD | Drawing drug from a vial |
11752257, | Sep 10 2014 | Becton, Dickinson and Company | Activation system and method for on-body medical devices |
11857769, | Jun 09 2016 | Becton, Dickinson and Company | Drive assembly and spacer for drug delivery system |
11904148, | Jun 09 2016 | Becton, Dickinson and Company | Actuator assembly for drug delivery system |
11951284, | Aug 27 2020 | Tandem Diabetes Care, Inc. | Transitioning to other modes in automated insulin delivery |
8573027, | Feb 27 2009 | TANDEM DIABETES CARE, INC | Methods and devices for determination of flow reservoir volume |
9250106, | Feb 27 2009 | Tandem Diabetes Care, Inc. | Methods and devices for determination of flow reservoir volume |
9555186, | Jun 05 2012 | TANDEM DIABETES CARE, INC | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
9962486, | Mar 14 2013 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
D805631, | Jan 21 2016 | Becton, Dickinson and Company | Drug delivery device with insertion mechanism button safety |
D806232, | Jan 21 2016 | Becton, Dickinson and Company | Drug delivery device with insertion mechanism |
D829889, | Jan 21 2016 | Becton, Dickinson and Company | Wearable drug delivery device with adhesive |
D829894, | Jan 21 2016 | Becton, Dickinson and Company | Wearable drug delivery device baseplate |
D830537, | Jan 21 2016 | Becton, Dickinson and Company | Wearable drug delivery device with adhesive and liner |
D830547, | Jan 21 2016 | Becton, Dickinson and Company | Adhesive liner for wearable drug delivery device |
D836193, | Jan 21 2016 | Becton, Dickinson and Company | Adhesive liner for wearable drug delivery device |
D857191, | Jan 21 2016 | Becton, Dickinson and Company | Wearable drug delivery device |
D878552, | Jan 21 2016 | Becton, Dickinson and Company | Wearable drug delivery device |
D878553, | Jan 21 2016 | Becton, Dickinson and Company | Wearable drug delivery device |
Patent | Priority | Assignee | Title |
4734092, | Feb 18 1987 | ALARIS MEDICAL SYSTEMS, INC ; ALARIS MEDICAL, INC | Ambulatory drug delivery device |
6605060, | Jun 07 1995 | O NEIL, ALEXANDER GEORGE BRIAN AND CHRISTINE O NEIL, JOINTLY | Patient controlled drug delivery device |
6702779, | Aug 18 2000 | Becton, Dickinson and Company | Constant rate fluid delivery device with selectable flow rate and titratable bolus button |
6824529, | Jun 24 1997 | Elan Pharma International Limited | Pre-filled drug-delivery device and method of manufacture and assembly of same |
6923791, | Mar 31 2003 | ICU Medical, Inc | Infusion device having offset flow path |
20020177809, | |||
20040068222, | |||
20050107743, | |||
20060270987, | |||
20070088267, | |||
20070213658, | |||
20070255236, | |||
20080033402, | |||
20080132842, | |||
CN1561237, | |||
CN1986009, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Sep 28 2007 | Calibra Medical, Inc. | (assignment on the face of the patent) | / | |||
Nov 07 2007 | CARTER, BRETT J | SEATTLE MEDICAL TECHNOLOGIES, INC | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 020336 | /0404 | |
Nov 07 2007 | ADAMS, JOHN M | SEATTLE MEDICAL TECHNOLOGIES, INC | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 020336 | /0404 | |
Dec 05 2007 | CROSS, BRETT | SEATTLE MEDICAL TECHNOLOGIES, INC | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 020336 | /0404 | |
Jun 16 2008 | SEATTLE MEDICAL TECHNOLOGIES, INC | CALIBRA MEDICAL, INC | CHANGE OF NAME SEE DOCUMENT FOR DETAILS | 021204 | /0708 | |
Dec 22 2011 | CALIBRA MEDICAL, INC | JOHNSON & JOHNSON DEVELOPMENT CORPORATION | SECURITY AGREEMENT | 027449 | /0936 |
Date | Maintenance Fee Events |
Oct 15 2015 | STOL: Pat Hldr no Longer Claims Small Ent Stat |
Jan 13 2016 | M1551: Payment of Maintenance Fee, 4th Year, Large Entity. |
Jan 16 2020 | M1552: Payment of Maintenance Fee, 8th Year, Large Entity. |
Jan 17 2024 | M1553: Payment of Maintenance Fee, 12th Year, Large Entity. |
Date | Maintenance Schedule |
Jul 31 2015 | 4 years fee payment window open |
Jan 31 2016 | 6 months grace period start (w surcharge) |
Jul 31 2016 | patent expiry (for year 4) |
Jul 31 2018 | 2 years to revive unintentionally abandoned end. (for year 4) |
Jul 31 2019 | 8 years fee payment window open |
Jan 31 2020 | 6 months grace period start (w surcharge) |
Jul 31 2020 | patent expiry (for year 8) |
Jul 31 2022 | 2 years to revive unintentionally abandoned end. (for year 8) |
Jul 31 2023 | 12 years fee payment window open |
Jan 31 2024 | 6 months grace period start (w surcharge) |
Jul 31 2024 | patent expiry (for year 12) |
Jul 31 2026 | 2 years to revive unintentionally abandoned end. (for year 12) |